Enliven Therapeutics Prices Upsized Public Offering for $400M Gross
Enliven Therapeutics, Inc. priced an upsized public offering of 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. The offering is expected to generate approximately $400.0 million in gross proceeds, with net proceeds to the company estimated at $376.0 million. The underwriters also have a 30-day option to purchase an additional 1,600,000 shares, which could increase net proceeds to $432.4 million. The offering is expected to close on June 15, 2026.
Key Highlights
- Priced upsized public offering of common stock and pre-funded warrants.
- Issued 8,933,334 common shares at $37.50 per share.
- Issued 1,733,333 pre-funded warrants at $37.499 per warrant.
- Expected gross proceeds of approximately $400.0 million.
- Expected net proceeds of approximately $376.0 million.
- Underwriters hold option for additional 1,600,000 shares.
- Net proceeds could reach $432.4 million if option exercised.
- Offering expected to close on June 15, 2026.
Price Impact
More from ELVN
Enliven Therapeutics Reports Positive Phase 1 Data for ELVN-001; FDA Aligns on Phase 3 Dose
Enliven Therapeutics Increases Authorized Common Stock to 200M
Enliven Therapeutics Q1 Net Loss Narrows to $23.6M; Cash $132.2M